9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.verified

NMTR

Price:

$0.0722

Market Cap:

$1.04M

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prev...[Read more]

Industry

Biotechnology

IPO Date

2016-07-11

Stock Exchange

NASDAQ

Ticker

NMTR

The PE Ratio as of July 2024 (TTM) for 9 Meters Biopharma, Inc. (NMTR) is -0.04

According to 9 Meters Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -95.16% compared to the average of -0.88 of the last 4 quarters.

9 Meters Biopharma, Inc. (NMTR) Historical PE Ratio (quarterly & annually)

How has NMTR PE Ratio performed in the past?

The mean historical PE Ratio of 9 Meters Biopharma, Inc. over the last ten years is -3.16. The current -0.04 PE Ratio has changed 35.29% with respect to the historical average. Over the past ten years (40 quarters), NMTR's PE Ratio was at its highest in in the September 2014 quarter at 0. The PE Ratio was at its lowest in in the September 2018 quarter at -55.40.

Quarterly (TTM)
Annual

Average

-3.16

Median

-2.00

Minimum

-9.15

Maximum

-0.36

9 Meters Biopharma, Inc. (NMTR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of 9 Meters Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 488.54%

Maximum Annual PE Ratio = -0.36

Minimum Annual Increase = -94.45%

Minimum Annual PE Ratio = -9.15

Quarterly (TTM)
Annual
YearPE RatioChange
2022-0.36-94.45%
2021-6.46366.64%
2020-1.38115.35%
2019-0.64-72.84%
2018-2.37-74.13%
2017-9.15488.54%
2016-1.55-30.15%
2015-2.2325.85%
2014-1.77-68.78%

9 Meters Biopharma, Inc. (NMTR) Average PE Ratio

How has NMTR PE Ratio performed in the past?

The current PE Ratio of 9 Meters Biopharma, Inc. (NMTR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.73

5-year avg

-2.24

10-year avg

-3.16

9 Meters Biopharma, Inc. (NMTR) PE Ratio vs. Peers

How is NMTR’s PE Ratio compared to its peers?

9 Meters Biopharma, Inc.’s PE Ratio is greater than Mereo BioPharma Group plc (-77.28), greater than Acumen Pharmaceuticals, Inc. (-3.07), greater than Day One Biopharmaceuticals, Inc. (-6.21), greater than Inozyme Pharma, Inc. (-4.27), greater than Galera Therapeutics, Inc. (-0.15), greater than Aileron Therapeutics, Inc. (-1.26), greater than Artelo Biosciences, Inc. (-0.70), greater than Histogen Inc. (-0.10), greater than Curis, Inc. (-0.79), greater than Timber Pharmaceuticals, Inc. (-0.07), greater than Kineta, Inc. (-0.44), greater than Candel Therapeutics, Inc. (-4.70), greater than MiNK Therapeutics, Inc. (-1.48), greater than Forte Biosciences, Inc. (-0.85), greater than AlloVir, Inc. (-0.48), greater than ZIVO Bioscience, Inc. (-3.21), greater than RenovoRx, Inc. (-2.15), greater than Tempest Therapeutics, Inc. (-1.44), greater than Ikena Oncology, Inc. (-1.14), greater than Catalyst Biosciences, Inc. (-0.44), less than MEI Pharma, Inc. (0.73), less than Magenta Therapeutics, Inc. (-0.04), greater than Kezar Life Sciences, Inc. (-0.45), greater than Vincerx Pharma, Inc. (-0.36), greater than Avenue Therapeutics, Inc. (-0.27),

Build a custom stock screener for 9 Meters Biopharma, Inc. (NMTR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 9 Meters Biopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

9 Meters Biopharma, Inc. (NMTR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 9 Meters Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is 9 Meters Biopharma, Inc.'s PE Ratio?

How is the PE Ratio calculated for 9 Meters Biopharma, Inc. (NMTR)?

What is the highest PE Ratio for 9 Meters Biopharma, Inc. (NMTR)?

What is the 3-year average PE Ratio for 9 Meters Biopharma, Inc. (NMTR)?

What is the 5-year average PE Ratio for 9 Meters Biopharma, Inc. (NMTR)?

How does the current PE Ratio for 9 Meters Biopharma, Inc. (NMTR) compare to its historical average?